Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts
Open Access
- 1 October 1996
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 119 (3) , 545-550
- https://doi.org/10.1111/j.1476-5381.1996.tb15706.x
Abstract
1 The effect of the phosphatase inhibitor, cantharidin (3–300 μm) on force of contraction was studied in isolated electrically driven right ventricular trabeculae carneae from human myocardium. 2 The positive inotropic effect of cantharidin started at a concentration of 100 μm with a positive inotropic effect to 199% and to 276% of the predrug value in nonfailing and failing human hearts, respectively. 3 Under basal conditions the contraction time parameters were prolonged in human heart failure vs. nonfailing preparations. However, the positive inotropic effect of cantharidin did not affect contraction time parameters. Thus, time to peak tension, time of relaxation and total contraction time were not shortened by cantharidin in nonfailing and failing preparations. 4 The phosphatase activity was unchanged in preparations from failing hearts compared to nonfailing hearts. 5 Cantharidin inhibited phosphatase activity in a concentration-dependent manner. The IC50 value of cantharidin was about 3 μm in both nonfailing and failing human myocardium. 6 The positive inotropic effect of cantharidin was similar in nonfailing and failing human hearts, accompanied by a similar inhibitory effect of cantharidin on the phosphatase activity. The positive inotropic effect of cantharidin in failing hearts was as strong as the effect of isoprenaline in nonfailing hearts. 7 It is concluded that the treatment with a phosphatase inhibitor may offer a new positive inotropic modality for the treatment of human heart failure.Keywords
This publication has 21 references indexed in Scilit:
- cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardiumCardiovascular Research, 1994
- Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2AFEBS Letters, 1993
- Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholambanEuropean Journal of Biochemistry, 1991
- Basal and Isoprenaline-Stimulated cAMP Content in Failing Versus Nonfailing Human Cardiac PreparationsJournal of Cardiovascular Pharmacology, 1989
- INCREASE IN MYOCARDIAL Gi-PROTEINS IN HEART FAILUREThe Lancet, 1988
- Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart.Journal of Clinical Investigation, 1988
- Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.Circulation Research, 1987
- Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human HeartsNew England Journal of Medicine, 1982
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976